NEW YORK, Aug. 26, 2015 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTC:AXIM) is proud to announce the latest appointment to its Board of Advisors: Mr. Joe Grace. A proven business and marketing powerhouse, Mr. Grace brings to AXIM® Biotech's Board of Advisors two decades of experience growing companies and brands including WebMD®, Medscape®, Perricone MD Cosmaceuticals, and Suzanne Somers' ThighMaster™. As the Head of Online Marketing at WebMD®, Mr. Grace is credited with growing this innovative health portal into the most trusted and successful source for online health information with over 25 million unique monthly visitors.
A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=35563
"We are very fortunate that Mr. Joe Grace has joined AXIM® Biotech's Board of Advisors," states Dr. George E. Anastassov, MD, DDS, MBA and CEO of AXIM® Biotech. "Mr. Grace's experience with creating top brands and charting their path to success within the health and wellness industry is in direct alignment with AXIM®'s goals for our hemp-based cosmetics, functional foods, pharmaceuticals, nutraceuticals, and clean energy. We look forward to working together with Mr. Grace as AXIM® introduces many new hemp innovations for consumers and patients worldwide."
A strategic problem solver and marketing innovator, Mr. Joe Grace has developed a robust network of consumer health and wellness brands. As an early proponent of direct-to-consumer (DTC) marketing in the healthcare industry, Mr. Grace worked with many of the top-tier brands in the industry to create highly efficient DTC marketing programs. His creativity and depth of marketing experience cover a broad range of consumer health products including prescription drugs, medical devices, over-the-counter (OTC) drugs, skincare, and patient education. Mr. Grace also has a deep understanding of the regulatory environment, including the FDA/FTC regulations that must be taken into consideration when creating successful DTC marketing programs.
"Medical marijuana is rapidly gaining acceptance as a new course of treatment for a significant range of hard-to-treat medical conditions," states Mr. Joe Grace. "Unfortunately, medical marijuana is not available in all 50 states. However, hemp contains the same therapeutic chemical cannabidiol or 'CBD' found in medical marijuana and it can be sold in all 50 states. AXIM® is an early mover in the CBD space with standardized products, novel delivery systems and credible research. In my view, AXIM® is ideally positioned to capitalize on the rapidly growing CBD market."
Currently under clinical investigation is pain and spasticity among Multiple Sclerosis patients. AXIM® Biotech's core belief is responsibility for environmental stewardship combined with development of innovative products to address current conditions with no known effective treatment. AXIM® Biotech has expanded their list of conditions with no known cure to include: Parkinson's disease, Alzheimer's disease/dementia, ADHD (attention deficit hyperactivity disorder), PTSD, TBI, concussions, autism, MS, spasticity, pain, RLS (restless leg syndrome), glaucoma, IBD, IBS and Crohn's disease.
Mr. Grace's responsibilities in his illustrious career also included working with top pharmaceutical and medical device brand sponsors to create ground-breaking DTC marketing campaigns to reach health-conscious consumers across over 20 therapeutic conditions. His health and wellness marketing experience includes prescription drugs, medical devices, OTC drugs, skincare, weight loss and more. As the Head of Marketing at Medscape®, Mr. Grace was responsible for growing the physician portal into one of the top-rated destinations for physician education. Mr. Grace has also worked extensively with private equity and venture capital firms on a broad range of health and wellness transactions.
A graduate of Cornell University, Mr. Grace holds a BS in Electrical Engineering and Computer Science. He also holds an MBA from the Johnson School of Management at Cornell University. Mr. Grace is currently one of 12 alumni invited to work with the faculty and students as an Entrepreneur in Residence at the Cornell's Johnson School of Business.
Mr. Grace continues, "As a healthcare marketing professional, I believe I can develop and implement highly efficient marketing strategies to reach the CBD market and drive market share while building an important new brand. There is a significant first-mover opportunity for AXIM® to become a major player and trusted brand in this important new market."
To arrange for media interviews, contact Andrew Hard, Public Relations Spokesperson, at Andrew.Hard@AXIMBiotechnologies.com or call 858-380-5478.
About AXIM® Biotechnologies:
AXIM® Biotechnologies (OTC:AXIM) is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
LEGAL DISCLOSURE
AXIM Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell, and distribute hemp-based products.
The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.
